Enhanced production of antibodies utilizing insolubilized immune complexes

• US 5,084,396 A
• Filed: 09/07/1990
• Issued: 01/28/1992
• Est. Priority Date: 06/20/1986
• Status: Expired due to Term

• Current Assignee: NeoRx Corporation
• Original Assignee: NeoRx Corporation
• Inventors: McIntyre, Robert F., Woodhouse, Clive S., Morgan, A. Charles Jr.
• Primary Examiner(s): Wax, Robert A.
• Assistant Examiner(s): Sisson, Bradley L.
• Application Number:
  US07/579,627
• Time in Patent Office: 508 Days
• Field of Search: 436/513, 424/88
• US Class Current: 530/388.8
• CPC Class Codes: A61K 2039/6056 Antibodies
• CPC Class Codes: A61K 2039/622 non-covalent binding
• CPC Class Codes: A61K 39/385 Haptens or antigens, bound to carriers
• CPC Class Codes: A61K 39/44 Antibodies bound to carriers
• CPC Class Codes: C07K 16/4266 against anti-tumor receptor Ig
• CPC Class Codes: C07K 2317/32 specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
• CPC Class Codes: Y10S 424/807 Monoclonal
• CPC Class Codes: Y10S 530/861 involving IgG3, IgG4, IgA, or IgY
• CPC Class Codes: Y10S 530/864 Monoclonal

Abstract

A method for enhancing production of antibodies through immunization with insolubilized immune complexes is disclosed. Purified antigen or heterogeneous antigen mixtures may be combined with polyclonal or monoclonal antibody and the resultant complex bound to an insolubilized matrix to form insolubilized immune complexes. Methods for improving the immunogenicity of a soluble antigen and for producing monoclonal anti-iodiotypic antibodies are also disclosed. Monoclonal antibodies that are specific for a distinct, as yet unrecognized epitope may be produced by another disclosed method . Insolubilized immune complexes, comprising antigen and antibody that is ether directly linked to Sepharose® or absorbed onto insolubilized protein A, and immunosorbents, comprising antibody absorbed onto insolubilized protein A, are also disclosed.

Claims

1. A method for producing a monoclonal antibody specific for an epitope distinct from that recognized by an existing monoclonal antibody, comprising the steps of:

absorbing a first monoclonal antibody directed against a first epitope of a polyvalent antigen onto an inert, insoluble matrix capable of binding immunoglobulin, thereby forming an immunosorbent;

combining said immunosorbent with said polyvalent antigen, forming an insolubilized immune complex wherein said first epitope is masked by said first monoclonal antibody;

immunizing an animal with said insolubilized immune complex;

fusing spleen cells from said immunized animal to myeloma cells to form a hybridoma capable of producing a second monoclonal antibody directed against a second epitope of said polyvalent antigen;

culturing said hybridoma to produce said second monoclonal antibody; and

collecting said second monoclonal antibody as a product of said hybridoma.

2. The method of claim 1 wherein said inert, insoluble matrix capable of binding immunoglobulin is selected from the group consisting of CNBr-activated agarose, CNBr-activated Sepharose®

, protein A-agarose, protein A-Sepharose®

, protein A-methacrylate beads, and anti-immunoglobulin-coated methacrylate beads.

3. The method of claim 1, comprising, after the step of absorbing the antibody, the additional step of crosslinking the antibody to the inert, insoluble matrix.

4. The method of claim 1, comprising, after the step of combining the antigen, the additional step of crosslinking the antibody and antigen.

5. The method of claim 1 wherein said antigen is a component of a heterogeneous mixture.

6. The method of claim 5 wherein said heterogeneous mixture is selected from the group consisting of human melanoma cell extract, human colon carcinoma extract, human breast carcinoma extract, and human lung carcinoma extract.

7. The method of claim 1 wherein said first epitope is a tumor-associated epitope recognized by monoclonal antibody NR-LU-10.

8. The method of claim 1 wherein the antigen is a tumor-associated antigen.

9. The method of claim 1 further comprising, after the step of culturing, the step of screening hybridoma culture medium to determine the presence of said second monoclonal antibody.

10. The method of claim 9 wherein the screening step is performed by double determinant ELISA.

11. The cell line NR-LU-01 A5791.

12. A monoclonal antibody produced by the cell line of claim 11.

13. The cell line NR-LU-02 A5792.

14. A monoclonal antibody produced by the cell line of claim 13.

15. The cell line NR-LU-03 A5793.

16. A monoclonal antibody produced by the cell line of claim 15.